Phaseline

Companies › SK Life Science

SK Life Science: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 4; Neurology, Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cenobamate (YKP3089)
GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor
GABRA1, GABRB2, GABRG2, GABRB3, GABRA4Phase 4Focal Onset Seizure; Partial EpilepsyMay 2027
Carisbamate
GABA transporter 1 (GAT-1) inhibitor
SLC6A4Phase 3SeizuresFeb 2027
SKL35501
NTSR1-targeting small molecule linked to alpha emitter 225Ac
NTSR1Phase 1Selected Advanced Solid TumorsJul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05067634Cenobamate (YKP3089)Phase 3Partial EpilepsyNeurologyOct 2026
NCT05219617CarisbamatePhase 3SeizuresNeurologyFeb 2027
NCT06453213Cenobamate (YKP3089)Phase 4Focal Onset SeizureNeurologyMay 2027
NCT07812805SKL35501Phase 1Selected Advanced Solid TumorsOncologyJul 2030

Targets

NTSR1 (1) SLC6A4 (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1)

Companies with the same targets

Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group Acacia Pharma Sedana Medical Intra-Cellular Therapies Otsuka AlgoTherapeutix Takeda

Companies built like this

AB Science Lipocine Pharmasoft Italfarmaco Suven Life Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.